Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$91.84 USD

91.84
642,960

+0.89 (0.98%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $91.82 -0.02 (-0.02%) 4:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

Zacks Equity Research

Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings

by Zacks Equity Research

Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.

Zacks Equity Research

AMN vs. HQY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMN vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Hold on to OPKO Health Stock for Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

Zacks Equity Research

ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.

Sanghamitra Saha headshot

Bet on Earnings Beat With 5 Top-Ranked Stocks

by Sanghamitra Saha

These top-ranked stocks are likely to beat on bottom line in their next releases.

Zacks Equity Research

Varian (VAR) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research

Varian (VAR) gains from core Oncology segment in fiscal Q1.

Zacks Equity Research

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.

Zacks Equity Research

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

by Zacks Equity Research

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

Zacks Equity Research

Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

by Zacks Equity Research

Solid prospects in the HSA industry consistently drive HealthEquity (HQY).

Zacks Equity Research

Here's Why You Should Invest in Intuitive Surgical Stock Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.

Zacks Equity Research

HealthEquity (HQY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

HealthEquity (HQY) closed the most recent trading day at $70.58, moving -1.64% from the previous trading session.

Zacks Equity Research

Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand

by Zacks Equity Research

Intuitive Surgical (ISRG) gains from solid international show in Q4.

Zacks Equity Research

NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.

Sapna Bagaria headshot

Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?

by Sapna Bagaria

Teladoc (TDOC) stock gains from from positive earnings pre-announcement and news to acquire InTouch Health.

Zacks Equity Research

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research

DexCom (DXCM) expects its strong product portfolio to consistently drive top line.

Zacks Equity Research

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

by Zacks Equity Research

Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

Zacks Equity Research

Allscripts Expands Partnership With PIH Health Through 2025

by Zacks Equity Research

Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.

Zacks Equity Research

Inogen (INGN) Announces Preliminary Q4 Results, Slashes View

by Zacks Equity Research

Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.

Zacks Equity Research

ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View

by Zacks Equity Research

ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.

Zacks Equity Research

Teladoc to Buy InTouch Health, Expand Reach in Virtual Care

by Zacks Equity Research

Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.

Zacks Equity Research

Here's Why You Should Add Cerner (CERN) to Your Portfolio

by Zacks Equity Research

Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion in the fourth quarter.

Zacks Equity Research

Here's Why You Should Hold on to AngioDynamics Stock Now

by Zacks Equity Research

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.

Zacks Equity Research

Walgreens Boots (WBA) Q1 Earnings Lag Estimates, Margins Fall

by Zacks Equity Research

Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.